Dynamic changes in pro-and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease

Neurobiology of Disease

Volumn 71, Issue 1, 2014, Pages 280-291

  Pisanu, Augusta ^a   Lecca, Daniela ^a   Mulas, Giovanna ^a   Wardas, Jadwiga ^b   Simbula, Gabriella ^a   Spiga, Saturnino ^c   Carta, Anna R ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c Department of Neuropsychopharmacology Institute of Pharmacology Polish Academy of Sciences ^*  (Italy)

Author keywords

Cytokines; Microglia; MPTP; Neuroprotection; Parkinson's disease; PPAR

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CD206 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; LYMPHOCYTE ANTIGEN; PROBENECID; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CYTOKINE; MESSENGER RNA; NEUROPROTECTIVE AGENT; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL POLARITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOPAMINERGIC NERVE CELL; DRUG EFFECT; MALE; MICROGLIA; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; CELL COUNT; CLASSIFICATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MPTP POISONING; NERVE DEGENERATION; PATHOLOGY;

ANIMALS; CELL COUNT; CELL POLARITY; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; MICE; MICROGLIA; MPTP POISONING; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; RNA, MESSENGER; THIAZOLIDINEDIONES; TYROSINE 3-MONOOXYGENASE;

EID: 84908084191     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.08.011     Document Type: Article

References (83)

1. Alvarez-Fischer D., Noelker C., Vulinović F., Grünewald A., Chevarin C., Klein C., Oertel W.H., Hirsch E.C., Michel P.P., Hartmann A. Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model. PLoS One 2013, 8:e61700.
2. Andrews Z.B., Zhao H., Frugier T., Meguro R., Grattan D.R., Koishi K., McLennan I.S. Transforming growth factor beta2 haploinsufficient mice develop age-related nigrostriatal dopamine deficits. Neurobiol. Dis. 2006, 21:568-575.
3. Arimoto T., Choi D.Y., Lu X., Liu M., Nguyen X.V., Zheng N., Stewart C.A., Kim H.C., Bing G. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol. Aging 2007, 6:894-906.
4. Barcia C., Sánchez Bahillo A., Fernández-Villalba E., Bautista V., Poza Y., Poza M., Fernández-Barreiro A., Hirsch E.C., Herrero M.T. Evidence of active microglia in substantia nigra pars compacta of Parkinsonian monkeys 1year after MPTP exposure. Glia 2004, 46:402-409.
5. Barcia C., Ros C.M., Annese V., Gómez A., Ros-Bernal F., Aguado-Yera D., Martínez-Pagán M.E., de Pablos V., Fernandez-Villalba E., Herrero M.T. IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis. 2011, 2:e142.
6. Bernardo A., Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr. Pharm. Des. 2006, 12:93-109.
7. Bernardo A., Levi G., Minghetti L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci. 2000, 12:2215-2223.
8. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 2002, 82:615-624.
9. Brodacki B., Staszewski J., Toczyłowska B., Kozłowska E., Drela N., Chalimoniuk M., Stepien A. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci. Lett. 2008, 2:158-162.
10. Carta A.R. PPAR-γ: therapeutic prospects in Parkinson's disease. Curr. Drug Targets 2013, 14:743-751.
11. Carta A.R., Pisanu A. Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?. Neurotox. Res. 2013, 23:112-123.
12. Carta A.R., Tronci E., Pinna A., Morelli M. Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment. Eur. J. Neurosci. 2005, 21:1196-1204.
13. Carta A.R., Frau L., Pisanu A., Wardas J., Spiga S., Carboni E. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience 2011, 194:250-261.
14. Chao C.C., Hu S., Peterson P.K. Glia, cytokines, and neurotoxicity. Neurobiology 1995, 2-3:189-205.
15. Ciesielska A., Joniec I., Przybyłkowski A., Gromadzka G., Kurkowska-Jastrzebska I., Członkowska A., Członkowski A. Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease. Acta Neurobiol. Exp. (Wars) 2003, 2:117-126.
16. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 2000, 20:558-567.
17. Croisier E., Moran L.B., Dexter D.T., Pearce R.K., Graeber M.B. Microglial inflammation in the Parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J. Neuroinflammation 2005, 2:14.
18. De Lella Ezcurra A.L., ChertoffM., Ferrari C., Graciarena M., Pitossi F. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol. Dis. 2010, 37:630-640.
19. Dehmer T., Heneka M.T., Sastre M., Dichgans J., Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 2004, 88:494-501.
20. Depino A.M., Earl C., Kaczmarczyk E., Ferrari C., Besedovsky H., del Rey A., Pitossi F.J., Oertel W.H. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci. 2003, 18:2731-2742.
21. Diab A., Hussain R.Z., Lovett-Racke A.E., Chavis J.A., Drew P.D., Racke M.K. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 148:116-126.
22. Fujisaka S., Usui I., Bukhari A., Ikutani M., Oya T., Kanatani Y., Tsuneyama K., Nagai Y., Takatsu K., Urakaze M., Kobayashi M., Tobe K. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 2009, 58:2574-2582.
23. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., Brooks D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 2006, 21:404-412.
24. Gonzalez-Aparicio R., Flores J.A., Fernandez-Espejo E. Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor β1 is enhanced after co-infusion in rats. Exp. Neurol. 2010, 226:136-147.
25. Goris A., Williams-Gray C.H., Foltynie T., Brown J., Maranian M., Walton A., Compston D.A., Barker R.A., Sawcer S.J. Investigation of TGFB2 as a candidate gene in multiple sclerosis and Parkinson's disease. J. Neurol. 2007, 254:846-848.
26. Harms A.S., Lee J.K., Nguyen T.A., Chang J., Ruhn K.M., Treviño I., Tansey M.G. Regulation of microglia effector functions by tumor necrosis factor signaling. Glia 2012, 2:189-202.
27. Hirsch E.C., Hunot S., Damier P., Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. Ann. Neurol. 1998, 44:S115-S120.
28. Hoozemans J.J., Veerhuis R., Rozemuller J.M., Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int. J. Dev. Neurosci. 2006, 24:157-165.
29. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003, 106:518-526.
30. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004, 13:159-170.
31. Jimenez S., Baglietto-Vargas D., Caballero C., Moreno-Gonzalez I., Torres M., Sanchez-Varo R., Ruano D., Vizuete M., Gutierrez A., Vitorica J. Inflammatory response in the hippocampus of pS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J. Neurosci. 2008, 28:11650-11661.
32. Johnston L.C., Su X., Maguire-Zeiss K., Horovitz K., Ankoudinova I., Guschin D., Hadaczek P., FederoffH.J., Bankiewicz K., Forsayeth J. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol. Ther. 2008, 8:1392-1399.
33. Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Beal M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2005, 191:331-336.
34. Kim S.R., Lee K.S., Park H.S., Park S.J., Min K.H., Jin S.M., Lee Y.C. Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma. Mol. Pharmacol. 2005, 68:1568-1575.
35. Krieglstein K., Suter-Crazzolara C., Hötten G., Pohl J., Unsicker K. Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons. J. Neurosci. Res. 1995, 42:724-732.
36. Leal M.C., Casabona J.C., Puntel M., Pitossi F.J. Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's disease?. Front. Cell. Neurosci. 2013, 7:53.
37. Ledeboer A., Brevé J.J., Poole S., Tilders F.J., Van Dam A.M. Interleukin-10, interleukin-4, and transforming growth factor-beta differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. Glia 2000, 2:134-142.
38. Lodge P.A., Sriram S. Regulation of microglial activation by TGF-beta, IL-10, and CSF-1. J. Leukoc. Biol. 1996, 4:502-508.
39. Lofrumento D.D., Saponaro C., Cianciulli A., De Nuccio F., Mitolo V., Nicolardi G., Panaro M.A. MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation 2011, 18:79-88.
40. Luchman D.W., Shao D., Song C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol. Behav. 2009, 1-2:130-138.
41. Luchtman D.W., Meng Q., Song C. Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. Behav. Brain Res. 2012, 226:386-396.
42. Luna-Medina R., Cortes-Canteli M., Alonso M., Santos A., Martínez A., Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. Biol. Chem. 2005, 280:21453-21462.
43. Lund S., Christensen K.V., Hedtjärn M., Mortensen A.L., Hagberg H., Falsig J., Hasseldam H., Schrattenholz A., Pörzgen P., Leist M. The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. J. Neuroimmunol. 2006, 180:71-87.
44. Luo Y., Yin W., Signore A.P., Zhang F., Hong Z., Wang S., Graham S.H., Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J. Neurochem. 2006, 97:435-448.
45. Marinova-Mutafchieva L., Sadeghian M., Broom L., Davis J.B., Medhurst A.D., Dexter D.T. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. J. Neurochem. 2009, 110:966-975.
46. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 2008, 5:45.
47. McGeer P.L., Itagaki S., Akiyama H., McGeer E.G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 1988, 24:574-576.
48. McGeer P.L., Schwab C., Parent A., Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol. 2003, 54:599-604.
49. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from Parkinsonian patients. Neurosci. Lett. 1994, 180:147-150.
50. Mogi M., Harada M., Kondo T., Narabayashi H., Riederer P., Nagatsu T. Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci. Lett. 1995, 193:129-132.
51. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile Parkinsonism and Parkinson's disease. Neurosci. Lett. 1996, 211:13-16.
52. Nolan Y., Maher F.O., Martin D.S., Clarke R.M., Brady M.T., Bolton A.E., Mills K.H., Lynch M.A. Role of interleukin-4 in regulation of age-related inflammatory changes in the hippocampus. J. Biol. Chem. 2005, 280:9354-9362.
53. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., Red Eagle A., Vats D., Brombacher F., Ferrante A.W., Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
54. Orr C.F., Rowe D.B., Halliday G.M. An inflammatory review of Parkinson's disease. Prog. Neurobiol. 2002, 68:325-340.
55. Park S.W., Yi J.H., Miranpuri G., Satriotomo I., Bowen K., Resnick D.K., Vemuganti R. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J. Pharmacol. Exp. Ther. 2007, 320:1002-1012.
56. Pascual G., Sullivan A.L., Ogawa S., Gamliel A., Perissi V., Rosenfeld M.G., Glass C.K. Anti-inflammatory and antidiabetic roles of PPARgamma. Novartis Found. Symp. 2007, 286:183-196.
57. Patzer A., Zhao Y., Stöck I., Gohlke P., Herdegen T., Culman J. Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. Eur. J. Neurosci. 2008, 28:1786-1794.
58. Perego C., Fumagalli S., De Simoni M.G. Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. J. Neuroinflammation 2011, 8:174.
59. Petroske E., Meredith G.E., Callen S., Totterdell S., Lau Y.S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001, 106:589-601.
60. Pott Godoy M.C., Tarelli R., Ferrari C.C., Sarchi M.I., Pitossi F.J. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008, 131:1880-1894.
61. Pratt B.M., McPherson J.M. TGF-beta in the central nervous system: potential roles in ischemic injury and neurodegenerative diseases. Cytokine Growth Factor Rev. 1997, 8:267-292.
62. Rentzos M., Nikolaou C., Andreadou E., Paraskevas G.P., Rombos A., Zoga M., Tsoutsou A., Boufidou F., Kapaki E., Vassilopoulos D. Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol. Scand. 2009, 5:332-337.
63. Ricote M., Glass C.K. PPARs and molecular mechanisms of transrepression. Biochim. Biophys. Acta 2007, 1771:926-935.
64. Rojo A.I., Innamorato N.G., Martín-Moreno A.M., De Ceballos M.L., Yamamoto M., Cuadrado A. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 2010, 58:588-598.
65. Roussa E., Von Bohlen Und Halbach O., Krieglstein K. TGF-beta in dopamine neuron development, maintenance and neuroprotection. Adv. Exp. Med. Biol. 2009, 651:81-90.
66. Sanchez-Guajardo V., Barnum C.J., Tansey M.G., Romero-Ramos M. Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 2013, 30:113-139.
67. Satoh N., Shimatsu A., Himeno A., Sasaki Y., Yamakage H., Yamada K., Suganami T., Ogawa Y. Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone. Diabetes Care 2010, 33:e7.
68. Sawada M., Suzumura A., Hosoya H., Marunouchi T., Nagatsu T. Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J. Neurochem. 1999, 4:1466-1471.
69. Sawada M., Imamura K., Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J. Neural Transm. Suppl. 2006, 70:373-381.
70. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 2009, 29:954-963.
71. Schintu N., Frau L., Ibba M., Garau A., Carboni E., Carta A.R. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox. Res. 2009, 16:127-139.
72. Schober A., Peterziel H., von Bartheld C.S., Simon H., Krieglstein K., Unsicker K. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action. Neurobiol. Dis. 2007, 25:378-391.
73. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., O'Callaghan J.P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J. 2006, 20:670-682.
74. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007, 28:551-558.
75. Swanson C.R., Joers V., Bondarenko V., Brunner K., Simmons H.A., Ziegler T.E., Kemnitz J.W., Johnson J.A., Emborg M.E. The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in Parkinsonian monkeys. J. Neuroinflammation 2011, 8:91.
76. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93:241-252.
77. Varga T., Czimmerer Z., Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim. Biophys. Acta 1812, 2011:1007-1022.
78. Varnum M.M., Ikezu T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch. Immunol. Ther. Exp. (Warsz) 2012, 60:251-266.
79. Walsh S., Finn D.P., Dowd E. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience 2011, 175:251-261.
80. Watson M.B., Richter F., Lee S.K., Gabby L., Wu J., Masliah E., Effros R.B., Chesselet M.F. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp. Neurol. 2012, 237:318-334.
81. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 2007, 150:963-976.
82. Xing B., Xin T., Hunter R.L., Bing G. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J. Neuroinflammation 2008, 5:4.
83. Xu J., Drew P.D. Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J. Immunol. 2007, 178:1904-1913.